{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:06:34Z","timestamp":1792202794494,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.msard.2023.104611","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T20:53:36Z","timestamp":1678222416000},"page":"104611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Clinical outcomes and prognostic factors in patients with optic neuritis related to NMOSD and MOGAD in distinct ethnic groups from Latin America"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-5726","authenticated-orcid":false,"given":"Edgar","family":"Carnero Contentti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo A.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Criniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Pettinicchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgardo","family":"Cristiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Patrucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Bribiesca Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"G\u00f3mez-Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Flores-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar Patricio","family":"Correa-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Toral Granda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Angelica","family":"Ortiz Yepez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson Alfredo","family":"Gualotu\u00f1a Pachacama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jefferson Santiago","family":"Piedra Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Galleguillos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Tkachuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora","family":"Nadur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Daccach Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibis","family":"Soto de Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Caride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Lana-Peixoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ignacio","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2023.104611_bib0010","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/jnnp-2014-310206","article-title":"MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study","volume":"87","author":"Akaishi","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2023.104611_bib0030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jneuroim.2016.02.004","article-title":"Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica","volume":"293","author":"Akaishi","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.104611_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103222","article-title":"Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease","volume":"56","author":"Akaishi","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"19","key":"10.1016\/j.msard.2023.104611_bib0023","doi-asserted-by":"crossref","first-page":"7234","DOI":"10.1073\/pnas.0508716103","article-title":"Admixture dynamics in Hispanics: a shift in the nuclear genetic ancestry of a South American population isolate","volume":"103","author":"Bedoya","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.msard.2023.104611_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103485","article-title":"Impact of rituximab in Mexican patients with Multiple Sclerosis-A single-center retrospective study","volume":"58","author":"Bribiesca-Contreras","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104611_bib0006","doi-asserted-by":"crossref","first-page":"e702","DOI":"10.1212\/NXI.0000000000000702","article-title":"HLA association in MOG-IgG\u2013 and AQP4-IgG\u2013related disorders of the CNS in the Dutch population","volume":"7","author":"Bruijstens","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2023.104611_bib0001","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J. Neuroinflam."},{"key":"10.1016\/j.msard.2023.104611_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102428","article-title":"Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice","volume":"45","author":"Carnero Contentti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104611_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102258","article-title":"Age at onset correlate with disability in Latin American aquaporin-4-IgG-positive NMOSD patients","volume":"44","author":"Carnero Contentti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2023.104611_bib0027","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1007\/s00415-020-09699-2","article-title":"Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort","volume":"267","author":"Carnero Contentti","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104611_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102742","article-title":"What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM)","volume":"49","author":"Carnero Contentti","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2023.104611_bib0056","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/14728214.2021.1919082","article-title":"Emerging drugs for the treatment of adult MOG-IgG-associated diseases","volume":"26","author":"Carnero Contentti","year":"2021","journal-title":"Exp. Opin. Emerg. Drug."},{"issue":"3","key":"10.1016\/j.msard.2023.104611_bib0007","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/ene.15178","article-title":"Chiasmatic lesions on conventional magnetic resonance imaging during the first event of optic neuritis in patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease in a Latin American cohort","volume":"29","author":"Carnero Contentti","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2023.104611_bib0009","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibodypositive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.msard.2023.104611_bib0037","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.msard.2023.104611_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102399","article-title":"Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica","volume":"45","author":"Ciotti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104611_bib0014","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2023.104611_bib0033","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1177\/1352458513515085","article-title":"Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset","volume":"20","author":"Collongues","year":"2013","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2023.104611_bib0016","article-title":"Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: data from a nationwide registry in Argentina","volume":"7","author":"Contentti","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2023.104611_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102683","article-title":"Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders","volume":"48","author":"Correa-D\u00edaz","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2023.104611_bib0043","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of Rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and metaanalysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104611_bib0039","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/ene.14746","article-title":"The long-term outcome of MOGAD: an observational national cohort study of 61 patients","volume":"28","author":"Deschamps","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2023.104611_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101413","article-title":"Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia","volume":"36","author":"Drulovic","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2023.104611_bib0053","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2023.104611_bib0042","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: a meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2023.104611_bib0034","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.msard.2018.02.022","article-title":"Short transverse myelitis in Chinese patients with neuromyelitis optica spectrum disorders","volume":"21","author":"Hu","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2023.104611_bib0048","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"Jeong","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104611_bib0015","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease:a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2023.104611_bib0029","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3389\/fneur.2020.00537","article-title":"relapse patterns in NMOSD: evidence for earlier occurrence of optic neuritis and possible seasonal variation","volume":"11","author":"Khalilidehkordi","year":"2020","journal-title":"Front. Neurol."},{"issue":"Pt 6","key":"10.1016\/j.msard.2023.104611_bib0017","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.msard.2023.104611_bib0021","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104611_bib0044","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211054157","article-title":"Efficacy and safety of immunosuppressive therapy in myelin oligodendrocyte glycoprotein antibody-associated disease: a systematic review and meta-analysis","volume":"14","author":"Lai","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"7","key":"10.1016\/j.msard.2023.104611_bib0004","doi-asserted-by":"crossref","first-page":"e1316","DOI":"10.1002\/cti2.1316","article-title":"Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"10","author":"Lopez","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.msard.2023.104611_bib0038","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder","volume":"77","author":"Lopez-Chiriboga","year":"2020","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/j.msard.2023.104611_bib0041","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12732","article-title":"Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease","volume":"2","author":"Mariano","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"9","key":"10.1016\/j.msard.2023.104611_bib0003","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104611_bib0046","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.msard.2023.104611_bib0035","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1212\/NXI.0000000000000468","article-title":"Mortality in neuromyelitis optica is strongly associated with African ancestry","volume":"5","author":"Mealy","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2023.104611_bib0018","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.msard.2023.104611_bib0020","series-title":"Optic Neuritis and Its Differential Diagnosis Oxford Medical Publications","author":"Perkin","year":"1979"},{"issue":"2","key":"10.1016\/j.msard.2023.104611_bib0022","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00415-015-7983-1","article-title":"Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up","volume":"263","author":"Piccolo","year":"2016","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2023.104611_bib0008","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104611_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103083","article-title":"Status of the neuromyelitis optica spectrum disorder in Latin America","volume":"53","author":"Rivera","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104611_bib0012","first-page":"1","article-title":"Multiple sclerosis and neuromyelitis optica spectrum disorder testing and treatment availability in Latin America","author":"Rojas","year":"2021","journal-title":"Neurol. Res."},{"issue":"6","key":"10.1016\/j.msard.2023.104611_bib0005","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spec trum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104611_bib0026","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1177\/1352458516685416","article-title":"Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: a multicenter retrospective study in Korea","volume":"23","author":"Seok","year":"2017","journal-title":"Mult. Scler. (Houndmills Basingstoke England)"},{"issue":"6","key":"10.1016\/j.msard.2023.104611_bib0028","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1212\/NXI.0000000000000607","article-title":"Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus","volume":"6","author":"Sepulveda","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104611_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103080","article-title":"Asian and African\/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence","volume":"53","author":"Soares-Dos-Reis","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104611_bib0052","article-title":"Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","author":"Spagni","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2023.104611_bib0047","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"Stellmann","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2023.104611_bib0045","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104611_bib0031","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2147\/OPTH.S295769","article-title":"Comparison of early- and late-onset NMOSD-related optic neuritis in thai patients: clinical characteristics and long-term visual outcomes","volume":"15","author":"Thongmee","year":"2021","journal-title":"Clin. Ophthalmol."},{"issue":"1","key":"10.1016\/j.msard.2023.104611_bib0019","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104611_bib0049","article-title":"Neuromyelitis optica spectrum disorder with anti-aquaporin-4 antibody: outcome prediction models","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2023.104611_bib0024","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2023.104611_bib0057","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Canadian Pediatric Demyelinating Disease Network. Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2023.104611_bib0002","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823001153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823001153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:05:33Z","timestamp":1761901533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823001153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":57,"alternative-id":["S2211034823001153"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104611","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes and prognostic factors in patients with optic neuritis related to NMOSD and MOGAD in distinct ethnic groups from Latin America","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104611","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104611"}}